-+ 0.00%
-+ 0.00%
-+ 0.00%

Why ImmunityBio (IBRX) Stock Is Up 7.0% And What's Next After Bladder Cancer Trial Results

Simply Wall St·11/19/2026 06:13:12
Listen to the news
  • ImmunityBio reported third quarter 2026 revenue of US$48.84 million and a net loss of US$184.55 million, while highlighting statistically significant efficacy results for ANKTIVA plus BCG in a 370 patient trial for BCG naïve high grade non muscle invasive bladder cancer.
  • ANKTIVA’s move into earlier stage bladder cancer, combined with new approval in Israel and an upcoming FDA filing, places ImmunityBio’s bladder cancer franchise under the spotlight as management works to scale a commercial business that is still absorbing heavy research and development and operating costs.
  • This article now examines how ImmunityBio’s investment narrative could shift as ANKTIVA progresses toward an FDA filing in BCG naïve disease.

Scan other oncology-focused opportunities that are moving on fresh data and regulatory catalysts with the hand picked 37 healthcare AI stocks, which could sit alongside a high-risk story like ImmunityBio.

ImmunityBio Investment Narrative Recap

To own ImmunityBio, investors effectively have to back ANKTIVA as the anchor of a broader immunotherapy platform and accept heavy investment spending while that thesis is tested. The latest quarter shows revenue of US$48.84 million alongside a net loss of US$184.55 million, so cash burn and negative shareholders’ equity remain front and center.

The near term story hinges on execution in bladder cancer, particularly ANKTIVA’s progress into earlier stage BCG naïve disease, while containing operating costs that reached a loss of US$1.05b over nine months. Recent data clarity and filing timelines influence that clinical and regulatory path more than day to day trading swings.

The final primary endpoint analysis from QUILT 2.005 in BCG naïve high grade non muscle invasive bladder cancer is the announcement that really matters here. ImmunityBio reported statistically significant efficacy for ANKTIVA plus BCG versus BCG alone in a 370 patient registrational trial, with a p value of 0.01 at six months.

That dataset underpins the planned supplemental BLA filing to let ANKTIVA be used with a patient’s first course of BCG. Operationally, this could test ImmunityBio’s ability to broaden use within urology, secure reimbursement in an earlier setting and scale manufacturing, while investors still weigh the risk that heavy R&D and commercialization spend keeps losses elevated.

ImmunityBio's narrative projects US$1.5b revenue and US$688.6 million earnings by 2029. That profile is built on analyst assumptions of yearly top line expansion of 106.7% and an earnings swing of about US$1.68b from current earnings of a US$992.4 million loss.

Uncover why ImmunityBio's fair value indicates a 113% potential upside to its current price that could narrow quickly.

NasdaqGS:IBRX 1-Year Stock Price Chart
NasdaqGS:IBRX 1-Year Stock Price Chart

Exploring Other Perspectives

One alternate angle on ImmunityBio focuses on the BCG naive catalyst. The most optimistic analysts were already modeling about US$2.4b of revenue and US$1.3b of earnings by 2029, compared with consensus expectations of US$1.5b and US$688.6 million. Those views were formed before this trial readout, so narratives may shift as fresh data is incorporated.

Explore 4 other ImmunityBio fair value estimates, including one that suggests as much as 551% upside from the current price.

The Verdict Is Yours

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking for more investment ideas beyond ImmunityBio?

If the ImmunityBio story has you thinking about position sizing and portfolio balance, it can help to line it up against other opportunities with very different risk profiles using the Simply Wall St Screener.